PHARMACOLOGY AND TOXICITY OF HIGH-DOSE CYTARABINE BY 72-HOUR CONTINUOUS INFUSION
- 1 September 1986
- journal article
- research article
- Vol. 70 (9) , 1059-1065
Abstract
Most studies using high-dose cytarabine (ara-c) for the therapy of acute leukemia have employed intermittent short infusions. In this study, we have evaluated the pharmacology and toxicity of high-dose ara-c by 72-hour continuous infusion. Plasma ara-c concentrations varied from 3.6 .mu.M at the starting dose of 4 g/m2/72 hours to 22.6 .mu.M at 18 g. Plasma clearance appeared to decrease progressively at doses > 10 g, suggesting that the route of elimination was saturable. CSF ara-c concentrations ranged from 1.2 .mu.M at 4 g to 4.1 .mu.M at 18 g; the ratio of CSF to plasma ara-c decreased progressively from 0.33 at 4 g to 0.18 at 18 g. The toxic effects were significant and included myelosuppression, nausea, and vomiting in all patients. No single dose-limiting toxicity was identified. Further dose escalation was precluded by combined organ system effects, which included hepatic, pulmonary, renal and gastrointestinal toxic effects. Attempts to incorporate a 72-hour infusion of ara-c into a combination chemotherapy regimen should proceed cautiously with a starting dose of 6 g/m2/72 hours.This publication has 16 references indexed in Scilit:
- A PILOT-STUDY OF HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE FOR ACUTE-LEUKEMIA AND REFRACTORY LYMPHOMA - CLINICAL-RESPONSE AND PHARMACOLOGY1982
- Chemotherapy of Leukemia in Mice, Rats, and Humans Relating Time of Humoral Stimulation, Tumor Growth, and Clinical Response23JNCI Journal of the National Cancer Institute, 1981
- Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemiaThe American Journal of Medicine, 1981
- Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemiaCancer, 1980
- A RATIONALE FOR SEQUENTIAL HIGH-DOSE CHEMOTHERAPY OF LEUKEMIA TIMED TO COINCIDE WITH INDUCED TUMOR PROLIFERATION1980
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Liver disease complicating the management of acute leukemia during remissionCancer, 1978
- Hyperbilirubinemia during induction therapy of acute granulocytic leukemiaCancer, 1977
- TIMED SEQUENTIAL THERAPY OF HUMAN LEUKEMIA BASED UPON RESPONSE OF LEUKEMIC-CELLS TO HUMORAL GROWTH-FACTORS1977
- CHEMOTHERAPY OF LEUKEMIA L1210 IN MICE WITH 1-BETA-D-ARABINOFURANOSYLCYTOSINE HYDROCHLORIDE .I. INFLUENCE OF TREATMENT SCHEDULES1966